Log in
Sign up
Golden has been acquired by ComplyAdvantage.Read about it here ⟶
‌

US Patent 11779549 Treatment of Fragile X Syndrome with cannabidiol

Patent 11779549 was granted and assigned to Zynerba Pharmaceuticals on October, 2023 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributorsActivity
Is a
Patent
Patent
Current Assignee
Zynerba Pharmaceuticals
Zynerba Pharmaceuticals
Date Filed
August 24, 2022
Date of Patent
October 10, 2023
Patent Applicant
Zynerba Pharmaceuticals
Zynerba Pharmaceuticals
Patent Application Number
17895008
Patent Citations
‌
US Patent 9447019 Fluorinated CBD compounds, compositions and uses thereof
‌
US Patent 9533942 Use of cannabidiol prodrugs in topical and transdermal administration with microneedles
‌
US Patent 9675656 Buccal and sublingual cannabinoid formulations and method of making the same
‌
US Patent 9730911 None
‌
US Patent 9782360 Fluorinated CBD compounds, compositions and uses thereof
‌
US Patent 9943491 Compressed tablet containing cannabidiol, method for its manufacture and use of such tablet in oral treatment of psychosis or anxiety disorders
‌
US Patent 10213390 Treatment of fragile X syndrome with cannabidiol
‌
US Patent 10314792 Treatment of autism with cannabidiol
‌
US Patent 10471022 Treatment of fragile X syndrome with cannabidiol
‌
US Patent 10555928 Cannabis extracts and methods of preparing and using same
•••
Patent Inventor Names
Marcel Bonn-Miller
Donna Gutterman
Nancy Tich
John Messenheimer
Terri Sebree
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
Patent Number
11779549
Patent Primary Examiner
‌
Michael V Meller

Find more entities like US Patent 11779549 Treatment of Fragile X Syndrome with cannabidiol

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo